Frontiers in Oncology,
Год журнала:
2024,
Номер
14
Опубликована: Окт. 11, 2024
Urinary
tumors
pose
a
significant
health
threat
because
of
their
high
prevalence
and
recurrence
rates.
Despite
the
availability
various
treatment
options,
many
patients
poorly
respond
to
traditional
therapies,
highlighting
urgent
need
for
alternative
approaches.
Oncolytic
viruses
are
promising
therapeutic
agents.
These
exploit
unique
characteristics
cancer
cells
specifically
target
destroy
them,
thereby
triggering
potent
antitumor
immune
responses.
This
review
delves
into
recent
advancements
future
prospects
oncolytic
viruses,
focusing
on
application
in
renal,
bladder,
prostate
cancers.
By
discussing
practical
implications
potential
different
including
cowpox
virus,
adenovirus,
measles
coxsackievirus,
reovirus,
we
pave
way
further
exploration
refinement
this
exciting
field.
Frontiers in Oncology,
Год журнала:
2025,
Номер
15
Опубликована: Фев. 7, 2025
Oncolytic
viruses
represent
a
distinct
class
of
that
selectively
infect
and
destroy
tumor
cells
while
sparing
normal
cells.
Despite
their
potential,
oncolytic
encounter
several
challenges
as
standalone
therapies.
Consequently,
the
combination
with
other
therapeutic
modalities
has
emerged
prominent
research
focus.
This
paper
summarizes
tumor-killing
mechanisms
viruses,
explores
integration
radiotherapy,
chemotherapy,
immune
checkpoint
inhibitors,
CAR-T,
CAR-NK
therapies,
provides
an
overview
related
clinical
trials.
By
synthesizing
these
advancements,
this
study
seeks
to
offer
valuable
insights
for
translation
virus
Herpes
simplex
virus
type
1
(HSV-1)
is
a
globally
widespread
that
causes
and
associates
with
wide
range
of
diseases,
including
herpes
encephalitis,
keratitis,
labialis.
The
interaction
between
HSV-1
the
host
involves
complex
immune
response
mechanisms,
recognition
viral
invasion,
maintenance
latent
infection,
triggering
reactivation.
Antiviral
therapy
core
treatment
for
infections.
Meanwhile,
vaccine
development
employs
different
strategies
methods,
several
promising
types
have
emerged,
such
as
live
attenuated,
protein
subunit,
nucleic
acid
vaccines,
offering
new
possibilities
prevention
infection.
Moreover,
can
be
modified
into
therapeutic
vector
gene
tumour
immunotherapy.
This
review
provides
an
in-depth
summary
infection-associated
innate
adaptive
responses,
disease
pathogenesis,
current
approaches,
recent
advances
in
development,
applications
cancer
treatment.
Through
systematic
multiple
aspects
HSV-1,
this
study
aims
to
provide
comprehensive
detailed
reference
public
on
prevention,
control,
HSV-1.
Cancers,
Год журнала:
2025,
Номер
17(5), С. 821 - 821
Опубликована: Фев. 27, 2025
Cancer
remains
a
leading
global
health
challenge,
placing
immense
burdens
on
individuals
and
healthcare
systems.
Despite
advancements
in
traditional
treatments,
significant
limitations
persist,
including
treatment
resistance,
severe
side
effects,
disease
recurrence.
Immunotherapy
has
emerged
as
promising
alternative,
leveraging
the
immune
system
to
target
eliminate
tumour
cells.
However,
challenges
such
immunotherapy
patient
response
variability,
need
for
improved
biomarkers
limit
its
widespread
success.
This
review
provides
comprehensive
analysis
of
current
landscape
cancer
immunotherapy,
highlighting
both
FDA-approved
therapies
novel
approaches
clinical
development.
It
explores
checkpoint
inhibitors,
cell
gene
therapies,
monoclonal
antibodies,
nanotechnology-driven
strategies,
offering
insights
into
their
mechanisms,
efficacy,
limitations.
By
integrating
emerging
research
advancements,
this
underscores
continued
innovation
optimise
overcome
existing
barriers.
Marine Drugs,
Год журнала:
2024,
Номер
22(7), С. 307 - 307
Опубликована: Июнь 30, 2024
Oncolytic
virotherapy
is
expected
to
provide
a
new
treatment
strategy
for
cancer.
Aphrocallistes
vastus
lectin
(AVL)
Ca2+-dependent
receptor
containing
the
conserved
domain
of
C-type
and
hydrophobic
N-terminal
region,
which
can
bind
bird’s
nest
glycoprotein
D-galactose.
Our
previous
studies
suggested
that
oncolytic
vaccinia
virus
(oncoVV)
armed
with
AVL
gene
exerted
remarkable
replication
antitumor
effects
in
vitro
vivo.
In
this
study,
we
found
oncoVV-AVL
may
reprogram
metabolism
hepatocellular
carcinoma
cells
promote
ROS,
elevated
ROS
subsequently
promoted
viral
induced
apoptosis.
This
study
will
theoretical
basis
application
liver
Experimental Hematology and Oncology,
Год журнала:
2025,
Номер
14(1)
Опубликована: Фев. 15, 2025
Abstract
Background
Glioblastoma
is
a
highly
aggressive
and
devastating
primary
brain
tumor
that
resistant
to
conventional
therapies.
Oncolytic
viruses
represent
promising
therapeutic
approach
for
glioblastoma
by
selectively
lysing
cells
eliciting
an
anti-tumor
immune
response.
However,
the
clinical
efficacy
of
oncolytic
often
hindered
challenges
such
as
short
persistence,
host
antiviral
responses,
T
cell
dysfunction.
Methods
We
have
developed
novel
strategy
“dressing”
with
anti-PD-1
antibodies
alendronate
(PD-1/Al@OV)
prevent
premature
clearance
enhance
function,
thereby
improving
immunotherapy
outcomes
against
glioma.
Results
found
in
high
reactive
oxygen
species
environment
tumor,
PD-1/Al@OV
disassembled
release
viruses,
anti-PD-1,
alendronate.
The
released
blocked
PD-1/PD-L1
pathway,
activating
cells;
eliminated
tumor-associated
macrophages,
increasing
concentration
viruses;
directly
lysed
cancer
cells,
enhancing
intratumoral
infiltration.
Conclusion
This
effectively
improved
immunosuppressive
microenvironment
achieved
robust
effect.
Consequently,
this
study
presents
combination
therapy
improvement
microenvironment,
offering
new
prospects
application
viruses.
Cancers,
Год журнала:
2025,
Номер
17(9), С. 1408 - 1408
Опубликована: Апрель 23, 2025
A
groundbreaking
milestone
in
oncology
has
been
the
recognition
and
targeted
elimination
of
malignant
cells
through
cancer
immunotherapy,
which
harnesses
body’s
immune
system
to
attack
[...]
Background:
While
Bacillus
Calmette-Guérin
(BCG)
remains
the
first-line
therapy
for
high-risk
bladder
cancer,
30-40%
of
patients
develop
treatment
resistance
necessitating
radical
cystectomy,
some
are
not
suitable
candidates
this
procedure.
This
underscores
critical
need
novel
therapeutic
approaches.
Emerging
clinical
evidence
has
increasingly
supported
potential
oncolytic
viruses
in
cancer
treatment.
Based
on
foundation,
we
investigated
anti-tumor
effects
KD01,
a
type
5
recombinant
adenovirus
previously
developed
by
our
team
engineered
to
express
truncated
BID
(tBID),
cancer.
Methods:
The
cytotoxic
and
efficacy
KD01
were
systematically
evaluated
across
human
cell
lines,
death
pathways
RNA
sequencing
validated.
Combination
studies
with
cisplatin
employed
testing.
In
final
stage,
safety
instillation
was
evaluated.
Results:
induced
through
multiple
mechanisms,
including
oncolysis,
immunogenic
death,
mitochondrial
apoptosis.
At
higher
doses,
combined
synergistically
inhibited
proliferation
Additionally,
amplified
damage-associated
molecular
patterns
(DAMPs)
release
immune
activation;
combination
further
enhanced
process.
Safety
evaluations
showed
favorable
tolerance
intravesical
perfusion
KD01.
Conclusions:
dual
action
directly
killing
tumor
cells
activating
immunity
its
as
agent.
These
findings
highlight
preclinical
informing
design
trials.
